Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events

Researchers wanted to understand how high levels of lipoprotein(a), a known genetic risk factor for cardiovascular disease (CVD), affect patients with established disease—particularly those taking statins.

Researchers wanted to understand how high levels of lipoprotein(a), a known genetic risk factor for cardiovascular disease (CVD), affect patients with established disease—particularly those taking statins. They conducted a meta-analysis of individual patient data from seven randomized, controlled trials that investigated outcomes with statin therapy. Based on information from more than 29,000 study participants, the team determined that starting on statins reduced LDL cholesterol without much of an effect on lipoprotein(a). Levels of lipoprotein(a) at baseline and on statins were roughly linear with CVD risk, with risk increasing at thresholds of 30 mg/dL or higher and 50 mg/dL or higher, respectively. The findings offer a rationale for testing the lipoprotein(a)-lowering hypothesis in studies with CVD endpoints, the review authors conclude.